Changing the Model for Lab Equipment Maintenance and Asset Management By Martin Long A large section of the Pharmaceutical, Biotech and supporting industries are currently driving aggressive cost-saving initiatives throughout their operations to remain competitive, and deliver shareholder value. One such area is the cost associated with maintaining laboratory instrumentation… Read More
The evolving world of drug discovery data integration in the pharmaceutical industry Dr David Sedlock The world of drug discovery has been impacted significantly by an ever evolving use of computer systems during the past 25 years with the greatest change occurring during the past 10 years or so as… Read More
By Dr Jean-Luc Vanderheyden As the experience and advances in Positron Emission Tomography (PET) imaging grows, so does the belief that this technology can have a key role to play in ushering in an era of personalised medicine while also offering an enormous contribution in reducing the attrition rates in… Read More
Lean Thinking for Drug Discovery – Better Productivity for Pharma By Dr Edward W. Petrillo Success in drug discovery controls the success of the pharmaceutical enterprise. The molecular structure of every drug candidate, and the body of knowledge that will guide its use in the treatment of disease, are established… Read More
India - Global pharmaceutical R&D powerhouse or contract research workshop? By Dr Matthew Howard In response to the ever-increasing costs of drug discovery and development, pharmaceutical industry leaders must constantly seek to increase productivity while simultaneously reducing costs and maintaining quality. Globalisation of drug discovery may provide such an opportunity,… Read More
Sharing Risks and Rewards - Basis for a turnkey pharma-biotech alliance in osteoarthritis Dr Andre Hoekema In June 2006, Galapagos and GlaxoSmithKline’s Center of Excellence for External Drug Discovery (CEEDD) formed a multi-year worldwide alliance to discover and develop novel drugs for osteoarthritis. The focus of the alliance will be… Read More
Kinase Screening and Profiling Products - Spoilt for choice By Dr John Comley The end user is spoilt for choice with the range of alternative offerings, methodologies and approaches currently available for kinase screening and profiling. Whereas wider coverage of the kinome was the principal focus of kinase profiling a… Read More
The Genome as a Tool for Drug Discovery and Development the Case for Embracing Complexity By Dr Kenneth C. Carter Conventional drug discovery and development is centred on a paradigm in which 'validated' targets are subjected to in vitro screens for the identification of new drug candidates. Molecular profiling using… Read More
Ion Channel Drug Targets: Unlocking the potential By Dr Dayle S. Hogg, Dr Philip Boden, Dr Geoff Lawton and Dr Roland Z. Kozlowski A striking number of drugs targeting ion channels have reached blockbuster status, generating $ billion revenues. In spite of the historical success of ion channels as therapeutic… Read More
Miniaturisation of Assay Development and Screening By Andreas Boettcher and Dr Lorenz M. Mayr In recent years we have seen a strong increase in the number of chemical compounds and molecular targets used for lead discovery by high-throughput screening among most Pharma and Biotech companies. This has caused a strong… Read More
Changing Dynamics in Dispense and Imaging Assays By Dr John Comley The prospects for a significant shift in dispense and imaging (D&I) assays towards a greater utilisation of calcium-mediated flash luminescence readouts appears to be finally under way. Driving this changing dynamic is the acceptance that assay sensitivity (better quality… Read More
Silence For Health - Development of RNA interference based cancer therapy By Dr Ansgar Santel RNA interference (RNAi) has become an invaluable tool for biomedical research. It is already routinely used as an indispensable approach for gene function analysis in basic biological research and for target identification as well as… Read More
Advances in laboratory automation for drug discovery By Charanya Ramachandran Laboratory automation has metamorphosed the realm of drug discovery over the years through two of major influential factors – cost benefit and error reduction. Automation has reframed the traditional drug discovery process by making feasible the identification of many targets… Read More
By Dr Amarpreet S Dhiman In terms of drug discovery and development, the role of nanotechnology currently lies in improving diagnostic methods, developing improved drug formulations and drug delivery systems for disease therapy. The breakthrough format of nanotechnology offers innovative solutions, giving researchers greater analytical capacity, improved data quality and… Read More
TR-FRET Based Assays - Getting better with age By Dr John Comley Despite having been available for nearly 15 years, TR-FRET based assays are still the preferred fluorescent assay format for many screeners. A recent survey ranked Cisbio’s TR-FRET product (HTRF) as the most frequently used generic assay technology. GPCR… Read More
Share Share Tweet Email Understanding the strategic importance of BIOMARKERS for the discovery and early development phases Understanding the strategic importance of BIOMARKERS for the discovery and early development phases By Dr Orest Hurko Biomarkers have become an increasingly hot topic in the pharmaceutical industry. How much of this is… Read More
